Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 520

1.

Should we aim for oral health to improve outcomes in chronic kidney disease?

Krane V, Wanner C.

Nephrol Dial Transplant. 2016 May 13. pii: gfw049. [Epub ahead of print] Review. No abstract available.

PMID:
27190378
2.

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.

Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E.

Orphanet J Rare Dis. 2016 May 4;11(1):54. doi: 10.1186/s13023-016-0441-z.

3.

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

Staplin N, Haynes R, Herrington WG, Reith C, Cass A, Fellström B, Jiang L, Kasiske BL, Krane V, Levin A, Walker R, Wanner C, Wheeler DC, Landray MJ, Baigent C, Emberson J; SHARP Collaborative Group.

Am J Kidney Dis. 2016 Apr 22. pii: S0272-6386(16)00699-5. doi: 10.1053/j.ajkd.2016.02.052. [Epub ahead of print]

4.

A Long Road to Travel: Adherence to Dietary Recommendations and Adequate Dietary Phosphorus Control.

Carrero JJ, Burrowes J, Wanner C.

J Ren Nutr. 2016 May;26(3):133-5. doi: 10.1053/j.jrn.2016.03.004. No abstract available.

PMID:
27105677
5.

Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y.

Oder D, Üçeyler N, Liu D, Hu K, Petritsch B, Sommer C, Ertl G, Wanner C, Nordbeck P.

BMJ Open. 2016 Apr 8;6(4):e010422. doi: 10.1136/bmjopen-2015-010422.

6.

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.

Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG.

J Med Genet. 2016 Mar 18. pii: jmedgenet-2015-103486. doi: 10.1136/jmedgenet-2015-103486. [Epub ahead of print]

7.

Soluble Urokinase Receptor and Chronic Kidney Disease.

Schumacher M, Wanner C, Beyersmann J.

N Engl J Med. 2016 Mar 3;374(9):890. doi: 10.1056/NEJMc1515787#SA2. No abstract available.

PMID:
26962916
8.

Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis.

Krane V, Schmidt KR, Gutjahr-Lengsfeld LJ, Mann JF, März W, Swoboda F, Wanner C; 4D Study Investigators (the German Diabetes and Dialysis Study Investigators).

Kidney Int. 2016 Jun;89(6):1380-7. doi: 10.1016/j.kint.2015.12.033. Epub 2016 Feb 17.

PMID:
26924051
9.

Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review.

Brück K, Jager KJ, Dounousi E, Kainz A, Nitsch D, Ärnlöv J, Rothenbacher D, Browne G, Capuano V, Ferraro PM, Ferrieres J, Gambaro G, Guessous I, Hallan S, Kastarinen M, Navis G, Otero Gonzalez A, Palmieri L, Romundstad S, Spoto B, Stengel B, Tomson C, Tripepi G, Völzke H, Wiȩcek A, Gansevoort R, Schöttker B, Wanner C, Vinhas J, Zoccali C, Van Biesen W, Stel VS; European CKD Burden Consortium.

Nephrol Dial Transplant. 2016 Apr;31(4):680. doi: 10.1093/ndt/gfw024. Epub 2016 Feb 5. No abstract available.

PMID:
26908763
10.

Clinical Monitoring of Protein-Energy Wasting in Chronic Kidney Disease: Moving From Body Size to Body Composition.

Carrero JJ, Wanner C.

J Ren Nutr. 2016 Mar;26(2):63-4. doi: 10.1053/j.jrn.2016.01.014. No abstract available.

PMID:
26897643
11.

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators.

Eur Heart J. 2016 May 14;37(19):1526-34. doi: 10.1093/eurheartj/ehv728. Epub 2016 Jan 26.

PMID:
26819227
12.

Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, Swinkels DW, Wanner C, Weiss G, Chertow GM; Conference Participants.

Kidney Int. 2016 Jan;89(1):28-39. doi: 10.1016/j.kint.2015.10.002.

13.

Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study.

Kollerits B, Drechsler C, Krane V, Lamina C, März W, Dieplinger H, Ritz E, Wanner C, Kronenberg F; German Diabetes and Dialysis Study Investigators.

Nephrol Dial Transplant. 2016 Jan 10. pii: gfv428. [Epub ahead of print]

PMID:
26754832
14.

CKD Prevalence Varies across the European General Population.

Brück K, Stel VS, Gambaro G, Hallan S, Völzke H, Ärnlöv J, Kastarinen M, Guessous I, Vinhas J, Stengel B, Brenner H, Chudek J, Romundstad S, Tomson C, Gonzalez AO, Bello AK, Ferrieres J, Palmieri L, Browne G, Capuano V, Van Biesen W, Zoccali C, Gansevoort R, Navis G, Rothenbacher D, Ferraro PM, Nitsch D, Wanner C, Jager KJ; European CKD Burden Consortium.

J Am Soc Nephrol. 2015 Dec 23. pii: ASN.2015050542. [Epub ahead of print]

PMID:
26701975
15.

Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia.

Locatelli F, Spasovski G, Dimkovic N, Wanner C.

Blood Purif. 2016;41(4):247-53. doi: 10.1159/000441648. Epub 2015 Dec 16.

PMID:
26670307
16.

Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy.

Krämer J, Bijnens B, Störk S, Ritter CO, Liu D, Ertl G, Wanner C, Weidemann F.

PLoS One. 2015 Nov 23;10(11):e0140627. doi: 10.1371/journal.pone.0140627. eCollection 2015.

17.

The Obesity Paradox and the Role of Inflammation.

Drechsler C, Wanner C.

J Am Soc Nephrol. 2016 May;27(5):1270-2. doi: 10.1681/ASN.2015101116. Epub 2015 Nov 23. No abstract available.

PMID:
26598516
18.

The fate of triaged and rejected manuscripts.

Zoccali C, Amodeo D, Argiles A, Arici M, D'arrigo G, Evenepoel P, Fliser D, Fox J, Gesualdo L, Jadoul M, Ketteler M, Malyszko J, Massy Z, Mayer G, Ortiz A, Sever M, Vanholder R, Vinck C, Wanner C, Więcek A.

Nephrol Dial Transplant. 2015 Dec;30(12):1947-50. doi: 10.1093/ndt/gfv387.

PMID:
26597920
19.

Electrical Changes in Resting, Exercise, and Holter Electrocardiography in Fabry Cardiomyopathy.

Krämer J, Nordbeck P, Störk S, Ritter C, Ertl G, Wanner C, Weidemann F.

JIMD Rep. 2015 Oct 27. [Epub ahead of print]

PMID:
26498960
20.

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.

Warnock DG, Thomas CP, Vujkovac B, Campbell RC, Charrow J, Laney DA, Jackson LL, Wilcox WR, Wanner C.

J Med Genet. 2015 Dec;52(12):860-6. doi: 10.1136/jmedgenet-2015-103471. Epub 2015 Oct 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk